Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
NCT06803680 · View on ClinicalTrials.gov ↗
Study Summary
The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims to answer are: * What is the recommended dosing for BGB-B455? * What medical problems do participants have when taking BGB-B455? The study has two parts: * Phase 1a: dose escalation and safety expansion * Phase 1b: dose expansion
Conditions Studied
Interventions
- DRUG Chemotherapy
- DRUG BGB-B455
Study Locations (13)
New South Wales
- Blacktown Cancer and Haematology Centre — Blacktown
- Liverpool Hospital — Liverpool
Florida
- Adventhealth — Celebration
Pennsylvania
- Sidney Kimmel Cancer Center — Philadelphia
South Dakota
- Avera Cancer Institute — Sioux Falls
Texas
- Next Oncology — San Antonio
Washington
- Fred Hutchinson Cancer Research Center — Seattle
Queensland
- Mater Cancer Care Centre — South Brisbane
Beijing Municipality
- Beijing Cancer Hospital — Beijing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-03-18 |
| Est. Completion | 2027-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06803680
The ClinicalTrials.gov registry entry for NCT06803680 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 91 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions — of which Chemotherapy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06803680 reports 13 study locations spanning 12 distinct geographic areas — top geographies include New South Wales, Florida, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06803680 about?
NCT06803680 is a clinical study titled "A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors". The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims to answer are: * What is the recommended dosing for BGB-B455? * What medical problems do participan...
What is the current status of trial NCT06803680?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2025-03-18. Estimated completion is 2027-10-30.
What conditions does trial NCT06803680 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumor. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06803680?
The interventions under investigation include: Chemotherapy (DRUG), BGB-B455 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06803680?
This trial is sponsored by BeiGene, which has 91 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06803680 being conducted?
This trial has 13 study locations across Florida, Pennsylvania, South Dakota, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.